hotspot -WSS

hotspot

author：focus 2025-09-27 22:47:49 - browse：8699

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： National associations that represent hospice owe an apology

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Abbott's new heart device gets FDA advisory panel nod

Latigo launches with $135 million for Vertex

Hospital at home shows how to bring innovation to health care

Meadows told special counsel he could not recall Trump ever declassifying Mar

Roche's accidental data boosts hopes for anti

focus

hotspot

Wikipedia

Activists slam private health insurers over coverage restrictions

Congress must protect the remaining independent doctors

Drug repurposing or repositioning? The language matters

As obesity drug market grows, telehealth companies court payers

Medicare proposal to cover medical devices draws a mixed reaction

California store owner shot dead in dispute over displaying Pride flag: Police

Walensky prepares to leave CDC — and Congress — behind

Kellogg’s is going to war over Mexico’s nutrition label rules

Cancer drug shortages should be causing more outrage

Abortion policy in the spotlight at Republican debate

knowledge

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Artificial intelligence use in health care faces greater scrutiny in 2024

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Study: Spinal cord stimulation helps patients with paralysis walk again

Study: Spinal cord stimulation helps patients with paralysis walk again

How the first Native Hawaiian psychiatrist helped diversify medicine

explore

hotspot

hotspot

entertainment